LVW Advisors Boosts Amgen Holdings by 44%

Institutional investor increases stake in biotech giant during Q4 2025

Mar. 29, 2026 at 10:18am

Got story updates? Submit your updates here. ›

LVW Advisors LLC, a financial advisory firm, reported increasing its holdings in Amgen Inc. (NASDAQ:AMGN) by 44.2% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 9,124 shares of the medical research company's stock, valued at $2.986 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics. Institutional investors closely monitor Amgen's stock performance and ownership changes, as the company's success is seen as a bellwether for the broader biotech industry.

The details

According to the 13F filing, LVW Advisors purchased an additional 2,798 shares of Amgen during the fourth quarter, bringing its total position to 9,124 shares. This represents a 44.2% increase in the firm's holdings of the biotech company's stock. Amgen's shares closed at $348.77 on Friday, giving LVW's position a market value of nearly $3 million.

  • LVW Advisors filed its 13F report for the fourth quarter of 2025 on March 29, 2026.
  • The firm increased its Amgen holdings during the three-month period ending December 31, 2025.

The players

LVW Advisors LLC

A financial advisory firm that manages investments and provides wealth management services.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The increase in LVW Advisors' Amgen holdings suggests the firm sees long-term growth potential in the biotech company. As a major player in the industry, Amgen's stock performance is closely watched by investors and analysts alike.